TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00265122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 4.5 mg/kg
Description: one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 4.5 mg/kg
Description: one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
Study: NCT04672720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 Mg
Description: Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-carnitine 1000 Mg
Description: Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
Study: NCT00265122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 4.5 mg/kg
Description: one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
Study: NCT03267927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion
Description: Fixation of rapid palatal expansion from day 0 to day 60

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGA™ system
Description: Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yoobreath™ system
Description: Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
Study: NCT04874363

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01414166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERN/LRPT
Description: ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
Study: NCT00258284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
Study: NCT04379544

Intervention type: OTHER
Intervention: Observation only
Description: There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
Study: NCT02404467

Intervention type: DEVICE
Intervention: TF TAVI
Description: Follow-up Observation of patients having received a TF-TAVI
Study: NCT01331733

Intervention type: DRUG
Intervention: hMG-HP

Intervention type: DRUG
Intervention: hMG + GnRH antagonist
Study: NCT00882466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human recombinant erythropoietin
Description: intravenous bolus injection of EPO (50unit/kg)
Study: NCT01877018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic reminder
Description: Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
Study: NCT00958568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine and Fluoxetine combination (OFC)
Description: Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 25 or 50 mg/day fixed dosing for 27 weeks
Study: NCT04088513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
Study: NCT01102322

Intervention type: BEHAVIORAL
Intervention: Quality
Description: Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
Study: NCT01279031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
Description: Comparison of vision after cataract surgery based on two different types of equipment.
Study: NCT02973529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb
Description: Randomization to implantation of Absorb BVS in bifurcation lesion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desolve
Description: Randomization to implantation of Desolve BRS in bifurcation lesion
Study: NCT01279031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon Infiniti wiht the OZIL Torsional Handpiece
Description: Comparision of vision after cataract surgery based on two different types of equipment.
Study: NCT02938039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu LMA
Description: Ambu Laryngeal Mask Airways

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel LMA
Description: I-Gel Laryngeal Mask Airways
Study: NCT00261118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
Study: NCT00608972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
Study: NCT02622230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mianhuahua Flavonoids Tablets
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match with experimental groups
Study: NCT01310504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Ultrasound
Description: Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
Study: NCT04385342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP-hMG
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP-hMG
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
Study: NCT04321642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entonox
Description: Entonox gas with mouth piece

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Not receive Entonox
Description: Not receive any gas
Study: NCT04495894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Ketorolac
Description: 30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
Study: NCT03246581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation
Study: NCT06631599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: The intervention consisted of physical exercise according to various protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: The intervention consisted of physical exercise according to various protocols
Study: NCT04005521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive intervention
Description: Preventive, structured exercise protocol
Study: NCT02242942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
Study: NCT06631352

Intervention type: OTHER
Intervention: Hepatopancreatoduodenectomy
Description: Pancreatoduodenectomy with liver resection

Intervention type: OTHER
Intervention: Hepatopancreatoduodenectomy
Description: Pancreatoduodenectomy with liver resection
Study: NCT02098031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving nutrition knowledge among mothers
Study: NCT01912326

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Implantation
Description: Implantation of a dual chamber pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Implantation
Description: Implantation of a dual chamber pacemaker
Study: NCT02820051

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous CO2 monitor
Description: Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitor
Description: Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
Study: NCT01310504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Ultrasound
Description: Paramedics will scan the abdomen and determine it there's fluid within.
Study: NCT01316471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Intervention
Description: The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education: Online Patient Education
Description: The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
Study: NCT03048474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab and ipilimumab
Study: NCT00718302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antiglide Plate
Description: A plate is placed behind the broken ankle and secured with screws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral Plate
Description: A metal plate is placed to the side of the broken ankle and is secured with screws
Study: NCT02820051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: The starting dose was 2 mg with additional doses of 1 mg if it was necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
Study: NCT02232763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 12 weeks of losartan or placebo with crossover to the other

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 12 weeks of losartan or placebo with crossover to the other
Study: NCT03184545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Standard physical therapy exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Standard physical therapy exercises
Study: NCT01224678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT04348370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
Study: NCT03161522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive induction chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT00093782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00560274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta [NeoRecormon]
Description: 30,000 IU sc/week (starting dose)
Study: NCT00063323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Study: NCT04606017

Intervention type: DRUG
Intervention: Caltrate Pill
Description: VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
Study: NCT04485507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-VR
Description: Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urban-VR
Description: Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
Study: NCT03607045

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: headless screw
Description: headless screw group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: headless screw
Description: headless screw group
Study: NCT00063323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Study: NCT00265122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
Study: NCT02081768

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90yttrium colloid
Description: 90yttrium colloid will be inserted into a sellar/parasellar cyst